EirGen Pharma Oncology Product Eir-080 Receives UK Approval

EirGen Pharma are pleased to announce that their oncology molecule “Eir-080” was approved for sale in the UK on 07-Aug-14. This product was developed for treatment of adults with newly-diagnosed glioblastoma multiforme, and also for the treatment of children 3 years and older and adult patients with malignant glioma.